

Amendments to the Claims**1.-22. (Cancelled)**

23. **(Currently Amended)** An isolated neuropilin binder (NPB), wherein the NPB is a monoclonal antibody, or antigen binding fragment thereof, that specifically binds ~~to-cell surface neuropilin-1 and inhibits angiogenesis of a cell expressing neuropilin-1 without inhibiting the binding of VEGF165 to neuropilin-1.~~

24. **(Previously Presented)** The NPB of claim 23, comprising the sequence set forth in SEQ ID No.: 15.

25. **(Previously Presented)** The NPB of claim 23, comprising a VH domain comprising amino acid residues 1 to 116 of the sequence set forth in SEQ ID No.: 15.

26. **(Previously Presented)** The NPB of claim 23, comprising a VL domain comprising amino acid residues 134 to 243 of the sequence set forth in SEQ ID No.: 15.

27. **(Previously Presented)** The NPB of claim 23, comprising a VH domain comprising CDR 1, 2 and 3 regions comprising amino acid residues 16 to 22, 40 to 56, and 89 to 105 respectively of the sequence set forth in SEQ ID No.: 15.

28. **(Previously Presented)** The NPB of claim 23, comprising a VL domain comprising CDR 1, 2 and 3 regions comprising amino acid residues 157 to 168, 184 to 190, and 222 to 232 respectively of the sequence set forth in SEQ ID No.: 15.

29. **(Previously Presented)** An isolated NPB, wherein the NPB is a monoclonal antibody, or antigen binding fragment thereof, that competes for binding to neuropilin-1 with the NPB claim 24.

30. **(Currently Amended)** A composition comprising the NPB according to any one of claims 23, 24, 25, 26, 27, 28, or 29 of claim 23, and a pharmaceutically acceptable carrier.

31. **(Currently Amended; Withdrawn)** A method of treating or preventing cancer or metastasis in a patient, the method comprising administering to the patient the NPB according to any one of claims 24, 25, 26, 27, 28, or 29 claim 23 or the composition according to claim 30 in an amount effective to inhibit neuropilin-1 mediated invasion and/or adhesion.